Skip to main content

Posts

Showing posts with the label blood glucose

Evaluation of Anti-diabetic Potentials of Methanol Extract of Ficus hispida Linn. Leaves against Alloxan Induced Diabetic Rats | Chapter 04 | Modern Advances in Pharmaceutical Research Vol. 3

Objective: The present study was designed to evaluate the acute and chronic effects of the methanol extract of Ficus hispida against alloxan (150 mg/kg) induced diabetic rats. Methods: In acute study, hypoglycemic potency of methanol  extract of Ficus hispida was assessed by oral glucose tolerance test (OGTT) and in chronic study of 21 days, extract at different doses (ie 100, 200 and 400 mg/kg) was screened  for its anti-diabetic activity. Blood glucose level had been estimated at 0, 7 th , 14 th and 21 st and addition to this serum concentrations of insulin, triglycerides, cholesterol, serum glutamate oxaloacetae transaminase (SGOT), serum glutamate pyruvate transaminase (SGPT) and urea determined at 21 st day of the study. Results: In OGTT, standard glibenclamide and extract (200 and 400 mg/kg) have shown significant reduction in blood glucose level compared to control group. In chronic model, the methanol extract was effective in reducing the blood glucose lev...

Effect of Organotherapic Medicine on Glycaemia in Patients and Animals Receiving Antiretroviral Therapy | Chapter 09 | New Insights into Disease and Pathogen Research Vol. 2

Aims: To evaluate the effect of an organotherapic drug, produced from the pancreas of a young pig, on glycemic alterations in AIDS patients. Methodology: Current study was carried out in a double-blind, placebo controlled and randomized design. AIDS patients who had high fasting glucose (>110 mg/dL) were selected so that the effect of the organotherapic drug could be evaluated. The patients were divided into two groups: Group I comprised patients who received the organotherapic drug diluted in 1x1012 alcohol/ water 8%, once a day, with a sublingual-administered fasting dose of 10 drops, during four months. Group II consisted of patients receiving placebo once a day at the same dosage. Glucose oxidase method and ELISA, following the manufacturer’s instructions, respectively determined levels of glucose and insulin before treatment and monthly until four months after the start of treatment. Results: Results registered hyperglycemia in 30% of the patients (60/200), hig...